238 related articles for article (PubMed ID: 32723083)
1. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
2. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibition: a promising strategy to prevent cancer immune editing.
Kang N; Eccleston M; Clermont PL; Latarani M; Male DK; Wang Y; Crea F
Epigenomics; 2020 Aug; 12(16):1457-1476. PubMed ID: 32938196
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Kim HJ; Cantor H; Cosmopoulos K
Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modification of Enhancer of Zeste Homolog 2 Modulates the Activation of Dendritic Cells in Allergen Immunotherapy.
Li H; Wen Y; Wu S; Chen D; Luo X; Xu R; Ma R; Wen W
Int Arch Allergy Immunol; 2019; 180(2):120-127. PubMed ID: 31256157
[TBL] [Abstract][Full Text] [Related]
6. The functions of EZH2 in immune cells: Principles for novel immunotherapies.
Shao FF; Chen BJ; Wu GQ
J Leukoc Biol; 2021 Jul; 110(1):77-87. PubMed ID: 33040370
[TBL] [Abstract][Full Text] [Related]
7. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
10. EZH2 as a mediator of treatment resistance in melanoma.
Tiffen JC; Gallagher SJ; Tseng HY; Filipp FV; Fazekas de St. Groth B; Hersey P
Pigment Cell Melanoma Res; 2016 Sep; 29(5):500-7. PubMed ID: 27063195
[TBL] [Abstract][Full Text] [Related]
11. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
Huang R; Wu Y; Zou Z
Epigenomics; 2022 Nov; 14(22):1449-1464. PubMed ID: 36601794
[TBL] [Abstract][Full Text] [Related]
12. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
13. The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy.
Wang Y; Bui T; Zhang Y
Int J Hematol; 2022 Dec; 116(6):837-845. PubMed ID: 36271224
[TBL] [Abstract][Full Text] [Related]
14. EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas.
DuCote TJ; Song X; Naughton KJ; Chen F; Plaugher DR; Childress AR; Gellert AR; Skaggs EM; Qu X; Liu J; Liu J; Li F; Wong KK; Brainson CF
Cancer Res Commun; 2024 Feb; 4(2):388-403. PubMed ID: 38265267
[TBL] [Abstract][Full Text] [Related]
15. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
[TBL] [Abstract][Full Text] [Related]
16. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
18. EZH2 as a Regulator of CD8+ T Cell Fate and Function.
Stairiker CJ; Thomas GD; Salek-Ardakani S
Front Immunol; 2020; 11():593203. PubMed ID: 33117406
[TBL] [Abstract][Full Text] [Related]
19. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
20. LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.
Guo W; Wang Y; Yang M; Wang Z; Wang Y; Chaurasia S; Wu Z; Zhang M; Yadav GS; Rathod S; Concha-Benavente F; Fernandez C; Li S; Xie W; Ferris RL; Kammula US; Lu B; Yang D
Sci Adv; 2021 Feb; 7(7):. PubMed ID: 33568470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]